TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8865515

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1746465

Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (0.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intracoronary diltiazem (0.5 mg) with placebo pretreatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intracoronary diltiazem (0.5 mg) with isosorbide dinitrate pretreatment
Number of subjects: 20
Study: 7102536

Group type: EXPERIMENTAL
Intervention: Propranolol (10, 20, and 40 mg four times a day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pindolol (2.5, 5, and 10 mg four times a day)
Number of subjects: 52
Study: 31595861

Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion program (8-week group-based adaptation)
Number of subjects: 27
Study: 30143387

Group type: EXPERIMENTAL
Intervention: Sodium chloride nasal gel at 6.0mg/g
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium chloride nasal gel at 4.5mg/g
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both concentrations (6.0mg/g and 4.5mg/g)
Number of subjects: 60
Study: 29016583

Group type: EXPERIMENTAL
Intervention: Transabdominal pre-peritoneal repair
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lichtenstein's hernioplasty
Number of subjects: 102
Study: 25835116

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Norfloxacin (Control)
Number of subjects: 70
Study: 25022116

Group type: EXPERIMENTAL
Intervention: Acupuncture (warming needling manipulation at key acupoints Hegu (LI 4) and Taichong (LR 3), once a day for 10 treatments, 2 sessions total)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (2.5 mg diazepam tablets, three times a day for 23 days)
Number of subjects: 60
Study: 22964862

Group type: EXPERIMENTAL
Intervention: Brief training program for providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More complete training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less training
Number of subjects: 0
Study: 20026538

Group type: EXPERIMENTAL
Intervention: Patients diagnosed with mediastinitis or endocarditis during follow-up
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Postoperative variables
Number of subjects: 838

Group type: COMPARATOR
Intervention: Type of antibiotic prophylaxis
Number of subjects: 838
Study: 18089867

Group type: EXPERIMENTAL
Intervention: Baseline HRQOL scores (EORTC QLQ-C30 and EORTC Brain Cancer Module)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Classical analysis
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Refined analyses
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: C indexes and R2 coefficients
Number of subjects: 247
Study: 14707430

Group type: EXPERIMENTAL
Intervention: Olive oil-based emulsion (0.16 g/kg/h for 3 hours)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Soybean oil + medium chain fatty acid (MCT) emulsion (0.16 g/kg/h for 3 hours)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined data on day 1
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both lipid emulsions
Number of subjects: 13
Study: 11367869

Group type: COMPARATOR
Intervention: Standard treatment (intramuscular methotrexate 12.5 mg/week, oral sulphasalazine 0.5 g b.i.d., indometacin 100 mg suppository at bed-time)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard treatment plus antioxidant combination
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High dose of vitamin E (400 mg t.i.d.) plus standard treatment
Number of subjects: 30
Study: 9226553

Group type: EXPERIMENTAL
Intervention: Capillary gas chromatography with nitrogen-phosphorus selective detection (NPD)
Number of subjects: 0
Study: 8428267

Group type: EXPERIMENTAL
Intervention: Bupivacaine wound infiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3676625

Group type: COMPARATOR
Intervention: Out-patient care
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Day hospital treatment (psychotherapy)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Day hospital treatment (all forms of day care)
Number of subjects: 106
Study: 31608503

Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD) alone (Group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Single-session ERCP combined with EUS-guided gallbladder drainage (Group B)
Number of subjects: 71
Study: 28710229

Group type: EXPERIMENTAL
Intervention: 14 days of antibiotic therapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Individualised duration determined by clinical response and 75% reduction in peak C reactive protein (CRP) values
Number of subjects: 500
Study: 26338453

Group type: EXPERIMENTAL
Intervention: Resistance training + healthy diet (RT-HD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study: 23257314

Group type: EXPERIMENTAL
Intervention: 3-mg po mibampator
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 22001199

Group type: EXPERIMENTAL
Intervention: 1,200 mg glucosamine sulfate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19723701

Group type: EXPERIMENTAL
Intervention: CRT plus ICD (1089 patients)
Number of subjects: 1820

Group type: COMPARATOR
Intervention: ICD alone (731 patients)
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: CRT plus ICD
Number of subjects: 1820

Group type: COMPARATOR
Intervention: CRT plus ICD and ICD alone
Number of subjects: 1820
Study: 17846273

Group type: EXPERIMENTAL
Intervention: AN1792(QS‐21) (synthetic beta‐amyloid plus an adjuvant)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (placebo)
Number of subjects: 372
Study: 15851238

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Number of subjects: 1153

Group type: COMPARATOR
Intervention: No angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI) in patients with congestive heart failure or impaired left ventricular function
Number of subjects: 1153
Study: 11437040

Group type: EXPERIMENTAL
Intervention: GIP needle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Wilson-Cook needle
Number of subjects: 30
Study: 10178333

Group type: EXPERIMENTAL
Intervention: Community-based smoking control intervention (4 years, 1989-1992)
Number of subjects: 9875
Study: 7526007

Group type: EXPERIMENTAL
Intervention: Repeated measures of American Urological Association symptom score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated measures of peak urine flow rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated measures of prostate specific antigen (PSA)
Number of subjects: 0
Study: 2752739

Group type: EXPERIMENTAL
Intervention: Lanolin allergens
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Purified anhydrous lanolin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Commercial cream containing 6% purified lanolin
Number of subjects: 33
Study: 1157005

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) (75 mg/m2/day)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: methotrexate (MTX) (25 mg/m2/twice weekly)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: cyclophosphamide (CYC) (100 mg/m2/day)
Number of subjects: 313
Study: 29800338

Group type: EXPERIMENTAL
Intervention: SBIRT-PM
Number of subjects: 101

Group type: COMPARATOR
Intervention: Pain Module counseling only
Number of subjects: 101

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 101
Study: 27208039

Group type: EXPERIMENTAL
Intervention: EN+PN
Number of subjects: 80

Group type: COMPARATOR
Intervention: EN
Number of subjects: 80
Study: 25312400

Group type: EXPERIMENTAL
Intervention: High physical activity (PA)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Limited screen time (ST)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Adequate fruits and vegetables consumption (FV)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Physical activity (PA)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Weight status (normal weight and overweight/obese)
Number of subjects: 384
Study: 23953528

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plasmalyte
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both NS and Plasmalyte
Number of subjects: 60
Study: 21741088

Group type: EXPERIMENTAL
Intervention: Infliximab with immunomodulator
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Infliximab in adults
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Concurrent immunomodulator use (purine antimetabolites or methotrexate)
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Development of antibodies to infliximab (ATIs)
Number of subjects: 692
Study: 19536422

Group type: EXPERIMENTAL
Intervention: Structured exercise program
Number of subjects: 424

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 424
Study: 17645255

Group type: EXPERIMENTAL
Intervention: Catgut implantation of points plus Wenlafaxin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simple oral administration of Wenlafaxin
Number of subjects: 70
Study: 15476688

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 8
Study: 11355435

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment using local points ST‐6, ST‐7, SI‐18, GV‐20, GB‐20, BL‐10 and distant point LI‐4, with needles manipulated to achieve De‐qui sensation and left in situ for 30 min, administered weekly for a total of six treatments.
Number of subjects: 6
Study: 9663368

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg-felodipine ER 2.5 mg once daily, titrated to a maximum of enalapril 10 mg-felodipine ER 10 mg if SiDBP not controlled after 4 weeks; Hydrochlorothiazide (HCTZ) 12.5 mg added if hypertension not controlled at maximum dose.
Number of subjects: 502

Group type: COMPARATOR
Intervention: Enalapril-felodipine ER combination with HCTZ 12.5 mg
Number of subjects: 502
Study: 8113301

Group type: EXPERIMENTAL
Intervention: Cartilage from OA knees
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control cartilage from cadaver knees
Number of subjects: 15
Study: 2571216

Group type: EXPERIMENTAL
Intervention: CGP 17582 B (50 mg orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propranolol (10 mg orally)
Number of subjects: 14
Study: 969072

Group type: EXPERIMENTAL
Intervention: Splinted pyeloplasty
Number of subjects: 129

Group type: COMPARATOR
Intervention: Unsplinted pyeloplasty
Number of subjects: 129
Study: 30165494

Group type: EXPERIMENTAL
Intervention: FDA‐mandated addiction warning
Number of subjects: 672

Group type: COMPARATOR
Intervention: Reduced‐risk warnings
Number of subjects: 672
Study: 28644774

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with chemotherapy (two doses of GO during induction and intensification)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Standard five-course chemotherapy alone (No-GO arm)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with chemotherapy
Number of subjects: 816
Study: 26196193

Group type: EXPERIMENTAL
Intervention: ECMO ± smoke inhalation acute lung injury (SALI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (ventilation only ± SALI)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ECMO groups
Number of subjects: 43
Study: 23657796

Group type: EXPERIMENTAL
Intervention: Ecosystem-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individually focused intervention
Number of subjects: 0
Study: 17063425

Group type: EXPERIMENTAL
Intervention: Systemic bevacizumab (5 mg/kg), administered three times at 2-week intervals.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1 mg), administered up to three times at 4-week intervals.
Number of subjects: 25
Study: 14560207

Group type: EXPERIMENTAL
Intervention: Color flow duplex ultrasound scanning (CDU)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Computed tomographic scan (CT)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Both CDU and CT
Number of subjects: 281
Study: 10320603

Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA) with background infusion (BI) at 15 microg x kg(‐1) x h(‐1) and bolus doses of 15 microg x kg(‐1) with a lock‐out interval of 10 min
Number of subjects: 47

Group type: COMPARATOR
Intervention: Continuous Infusion (CI) at 20 to 40 microg x kg(‐1) x h(‐1)
Number of subjects: 47
Study: 8938091

Group type: EXPERIMENTAL
Intervention: Reduced antenatal visit schedule (7 visits for nulliparous women, 6 visits for multiparous women)
Number of subjects: 1882

Group type: COMPARATOR
Intervention: Traditional antenatal visit schedule (13 visits)
Number of subjects: 1882
Study: 1725912

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 2
Study: 6412795

Group type: COMPARATOR
Intervention: Metoprolol (200 mg) plus Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg) plus Chlorthalidone (25 mg)
Number of subjects: 30
Study: 31808594

Group type: EXPERIMENTAL
Intervention: Ivermectin 0.4 mg/kg, orally, once 2 hours before infection
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30153737

Group type: EXPERIMENTAL
Intervention: Comprehensive smoking treatment including individual counseling, free pharmacotherapy (dual nicotine replacement therapy or varenicline), and 5 weeks of contingency management.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Delayed intervention control sites (no treatment during the study period).
Number of subjects: 25
Study: 27895268

Group type: EXPERIMENTAL
Intervention: Health education integrated into microcredit lending groups
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mixed-gender groups
Number of subjects: 138
Study: 25209353

Group type: EXPERIMENTAL
Intervention: Internet intervention for cancer survivors
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Social networking components of the intervention
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Early engagement
Number of subjects: 296
Study: 23033858

Group type: EXPERIMENTAL
Intervention: Encouraging symbolic gesture (baby sign)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition (no gesture training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gesture training for mothers
Number of subjects: 40
Study: 21252018

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with bare metal stents (BMS)
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1812
Study: 18214425

Group type: EXPERIMENTAL
Intervention: CPAP (with PEEP 10 cmH2O)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PAV (with PEEP 5‐6 cmH2O)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 36

Group type: COMPARATOR
Intervention: PAV
Number of subjects: 36
Study: 16611273

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg maintenance every 8 weeks
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo maintenance
Number of subjects: 282
Study: 12848836

Group type: EXPERIMENTAL
Intervention: Cancer prevention intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smaller churches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Churches without recent health activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pastors with less educational attainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pastors making personal lifestyle changes
Number of subjects: 0
Study: 11194088

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study: 8869676

Group type: EXPERIMENTAL
Intervention: Esmolol infusion (mean rate 330 +/- 10 micrograms/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine anesthesia (control group)
Number of subjects: 20
Study: 1531487

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Treatment by general practitioner (GP)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo therapy (detuned ultrasound and detuned short wave diathermy)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: All therapies (including manual therapy, physiotherapy, GP treatment, and placebo)
Number of subjects: 256
Study: 6845352

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg (divided doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ethanol (50 ml/70 kg body weight)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined propranolol and ethanol
Number of subjects: 12
Study: 31810456

Group type: EXPERIMENTAL
Intervention: Free paracetamol distribution (experimental arm)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 117
Study: 30217233

Group type: EXPERIMENTAL
Intervention: SMART Work & Life intervention with height-adjustable desk (group 1)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: SMART Work & Life intervention without height-adjustable desk (group 2)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: SMART Work & Life intervention (with or without desk)
Number of subjects: 660
Study: 27442691

Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (STCM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard treatment alone (STA)
Number of subjects: 65
Study: 25196301

Group type: EXPERIMENTAL
Intervention: Synbiotic bread (Lactobacillus sporogenes 1 × 10(8) CFU, 0.07 g inulin per 1 g)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Synbiotic bread
Number of subjects: 81

Group type: COMPARATOR
Intervention: Probiotic bread
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 81
Study: 22615088

Group type: EXPERIMENTAL
Intervention: Medication reconciliation phone call from a medical resident within 72 hours after discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no phone call)
Number of subjects: 0
Study: 20671557

Group type: EXPERIMENTAL
Intervention: 53.2 +/- 0.8% xenon
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.6 +/- 0.1% sevoflurane
Number of subjects: 40
Study: 18297983

Group type: EXPERIMENTAL
Intervention: Family presence during CPR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health care workers' acceptance of family presence
Number of subjects: 0
Study: 15885334

Group type: EXPERIMENTAL
Intervention: Lidocaine with adrenaline soaked swabs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline-soaked swabs (Control)
Number of subjects: 0
Study: 12011970

Group type: EXPERIMENTAL
Intervention: HR (Paroven, Venoruton; 0‐(beta‐hydroxyethyl)‐rutosides), 1g sachets, twice daily, for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10466952

Group type: EXPERIMENTAL
Intervention: Processed CPB blood using Continuous AutoTransfusion System (CATS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unprocessed CPB blood (control group)
Number of subjects: 20
Study: 8579351

Group type: EXPERIMENTAL
Intervention: Gender-stereotyped health interview
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonstereotyped health interview
Number of subjects: 38
Study: 2319479

Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine 56 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine 18 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 377152

Group type: EXPERIMENTAL
Intervention: 2g metronidazole rectal suppositories
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 31787562

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs (2 g twice daily)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs + NX (220 mg twice daily)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: NX (220 mg twice daily)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard nutrition counseling (control)
Number of subjects: 4
Study: 27918780

Group type: EXPERIMENTAL
Intervention: Proposed trastuzumab biosimilar
Number of subjects: 500

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 500
Study: 26310131

Group type: EXPERIMENTAL
Intervention: Gluten-containing flour
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gluten-free flour
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 35
Study: 23294622

Group type: EXPERIMENTAL
Intervention: Propofol (group P, N=46)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sevoflurane (group S, N=42)
Number of subjects: 88
Study: 21068692

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine
Number of subjects: 433

Group type: COMPARATOR
Intervention: Separate Hib-TT and MenC-CRM197 vaccines
Number of subjects: 433
Study: 19228863

Group type: EXPERIMENTAL
Intervention: Pedometers and text messaging
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 78
Study: 16881424

Group type: EXPERIMENTAL
Intervention: Missile trocar
Number of subjects: 100

Group type: COMPARATOR
Intervention: Veress needle
Number of subjects: 100
Study: 15006828

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 35
Study: 11704315

Group type: EXPERIMENTAL
Intervention: 200 mg/m(2) amifostine i.v. 30 min before radiation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 73